Physician profile
Hugh E Shearer
NPI 1316974579
$3,825.50
in general payments reported to CMS, 2019-2025
36 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,237 · 2020: $308 · 2021: $361 · 2022: $408 · 2023: $520 · 2024: $558 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,112.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $391.42 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Pfizer INC. | $390.60 | 2019-2025 | |
| Lilly USA, LLC | $187.32 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Supernus Pharmaceuticals, INC. | $138.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.21 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $119.70 | 2019-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $114.63 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $101.78 | 2019-2021 | |
| Amarin Pharma, INC. | $86.74 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $83.27 | 2019-2021 | |
| Amgen INC. | $80.35 | 2023-2025 | Repatha, Otezla, Repatha |
| Grifols USA, LLC | $67.67 | 2019-2023 | Prolastin-C Liquid |
| Collegium Pharmaceutical, INC. | $64.98 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $60.52 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $57.66 | 2019 | |
| Astellas Pharma US INC | $55.37 | 2019-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $54.39 | 2022-2023 | Rexulti |
| Daiichi Sankyo INC. | $50.56 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $49.11 | 2024-2025 | Airsupra |
| Abbvie INC. | $44.22 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $41.05 | 2019 | |
| Gilead Sciences, INC. | $38.55 | 2020 | |
| Allergan, INC. | $35.71 | 2019-2020 | |
| Boston Scientific Corporation | $31.57 | 2023 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.16 | 2023 | Xifaxan, Trulance |
| Shire North American Group INC | $30.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.49 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $29.15 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $22.47 | 2023 | |
| Ucb, INC. | $21.99 | 2023 | |
| Shield Therapeutics INC | $19.82 | 2025 | |
| Jazz Pharmaceuticals INC. | $15.79 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.74 | 2021 | |
| Genentech USA, INC. | $13.21 | 2020 | |
| Sanofi Pasteur INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugh Shearer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.